Shree Ganesh Remedies Ltd. (SGRL): Shree Ganesh Remedies Share Price Falls 9.22% to Rs 484: What Today’s Decline Signals

Shree Ganesh Remedies Ltd. fell to Rs 484, down 9.22% today, with market capitalisation at Rs 783.16 crore and turnover at Rs 1.75 crore on BSE.

Shree Ganesh Remedies Share Price fell to Rs 484 on 14 August 2026, a decline of 9.22% from the previous close of Rs 533.15, putting the micro-cap pharmaceutical stock among the top decliners today. With a market capitalisation of Rs 783.16 crore, the stock’s move stands out because it was large enough to qualify under the price fall threshold event for its market-cap category, even though the supplied data does not establish a company-specific catalyst behind the selling.

Shree Ganesh Remedies Share Price Today also reflected a weak intraday structure. The stock opened at Rs 530.55, which was also the day’s high, and then slipped to a low of Rs 476.75 before trading at Rs 484 at the time captured in the data. That sequence suggests the pressure built after the open rather than after a late spike. On BSE, total traded volume stood at 36,073 shares, with turnover at Rs 1.75 crore.

For investors tracking Shree Ganesh Remedies Stock News, the main takeaway is straightforward: the verified data confirms a sharp same-day share price decline, but it does not confirm why the stock is falling today. That still makes the move relevant in Stock Market Today and Share Market Today discussions because price action, valuation, profitability and sector positioning can all shape how such a decline is interpreted. In this Univest review, the focus is on what the numbers say now, what the Healthcare and Pharmaceuticals & Drugs benchmark shows, and what investors may want to monitor next.

Shree Ganesh Remedies Ltd. (SGRL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 484
Previous Close	Rs 533.15
Today's Change	Rs -49.15 (-9.22%)
Day Open	Rs 530.55
Day High	Rs 530.55
Day Low	Rs 476.75
Current Volume (BSE)	36,073
BSE Traded Volume	36,073
Combined NSE + BSE Volume	36,073
Turnover	Rs 1.75 crore
Market Capitalisation	Rs 783.16 crore
Market Cap Category	Micro Cap

Shree Ganesh Remedies Ltd. (SGRL) traded at Rs 484. versus the previous close of Rs 533.15, a fall of 9.22%. The stock opened at Rs 530.55, reached Rs 530.55, touched Rs 476.75. Reported volume was 36,073.

Shree Ganesh Remedies Ltd. (SGRL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 783.16 crore
P/E Ratio	44.34x
P/B Ratio	4.2x
ROE	21.18%
ROCE	27.51%
EPS	Rs 12.02
Dividend Yield	0%

Shree Ganesh Remedies Ltd. was valued at a P/E ratio of 44.34x, a P/B ratio of 4.2x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 21.18% and ROCE of 27.51%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 12.02, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Shree Ganesh Remedies Share Price may be weak today, but the supplied fundamentals add useful context rather than a simple one-line verdict. The company’s market capitalisation is Rs 783.16 crore, and its price-to-earnings ratio is 44.34 while its price-to-book ratio stands at 4.2. Those are valuation multiples, and they indicate that the market has been assigning a meaningful premium to the business relative to its accounting book value and earnings base.

Profitability ratios are stronger than many investors may expect from a stock that has turned into one of the day’s top losers. Return on equity is 21.18% and return on capital employed is 27.51%, both of which point to a business that has generated solid returns on shareholder equity and capital employed based on the latest supplied figures. That is an important part of Shree Ganesh Remedies Fundamental Analysis because it separates stock price volatility from operating efficiency.

The earnings profile is also visible through earnings per share of 12.02. In simple terms, EPS shows earnings attributable to each share, and an EPS of 12.02 helps explain why the stock carries a measurable, though not low, earnings multiple. The dividend yield is 0, which means the current data does not indicate a cash payout yield relative to the prevailing market price. For investors comparing income and growth profiles, that matters when assessing how the stock fits within the broader pharmaceutical pack.

Shree Ganesh Remedies Share Price also invites a closer look at the relationship between valuation and profitability. A P/E of 44.34 is not low in isolation, and a P/B of 4.2 also places the stock above many deep-value screens. Yet ROE of 21.18% and ROCE of 27.51% show that the company’s underlying return ratios are not weak. In other words, the supplied data suggests a company that has been profitable on capital metrics, but whose valuation still requires scrutiny after a sudden market decline.

For Univest readers following Shree Ganesh Remedies Earnings, Shree Ganesh Remedies Financial Results and broader stock analysis, today’s decline does not erase those underlying ratios. Instead, it raises the question of whether the market is re-pricing the stock, reacting to sentiment, or simply witnessing a bout of selling pressure without a disclosed company-specific trigger in the supplied data. That makes sector and peer context especially important.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	44.34x
Benchmark Median P/E	24.41x
Benchmark Average P/E	70.52x
Benchmark P/E Range	3.29x to 3,299.57x
Company P/B Ratio	4.2x
Benchmark Median P/B	1.75x
Company ROE	21.18%
Benchmark Median ROE	10.49%
Company ROCE	27.51%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 783.16 crore
Benchmark Median Market Cap	Rs 146.81 crore

Shree Ganesh Remedies Ltd. (SGRL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Shree Ganesh Remedies Ltd. (SGRL) has a P/E ratio of 44.34x, which is above the benchmark median of 24.41x, a difference of +81.65%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Shree Ganesh Remedies Ltd. (SGRL) has a ROE of 21.18%, which is above the benchmark median of 10.49%, a difference of +101.91%. Shree Ganesh Remedies Ltd. (SGRL) has a ROCE of 27.51%, which is above the benchmark median of 12.97%, a difference of +112.1%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Shree Ganesh Remedies Share Price sits within the Healthcare sector and the Pharmaceuticals & Drugs industry, and the supplied benchmark gives a detailed way to frame today’s fall. Across 136 companies in the same industry benchmark scope, the stock’s valuation and profitability metrics can be compared directly with the industry’s median, average and range instead of being judged in isolation.

The most immediate comparison is valuation. Shree Ganesh Remedies Share Price trades at a P/E of 44.34. In the same industry dataset, the median P/E is 24.41 and the average is 70.52, based on 104 companies, with a wide range from 3.29 to 3299.57. That places the company above the industry median but below the average. On a P/B basis, the company is at 4.2 versus a median of 1.75 and an average of 2.51 across 135 companies, with the range running from -10.01 to 16.63. That suggests the stock is valued above the typical industry book multiple.

Profitability looks stronger than the benchmark median and average. Company ROE is 21.18%, above the same-industry median of 10.49% and average of 8.1 across 135 companies. Company ROCE is 27.51%, again above the median of 12.97% and average of 15.53 for 135 companies. That is a constructive point in Shree Ganesh Remedies Fundamental Analysis because it shows the stock’s return profile is stronger than broad industry central tendencies.

Size also matters. Shree Ganesh Remedies Market Cap of Rs 783.16 crore sits above the industry median market capitalisation of Rs 146.81 crore and the average of Rs 489.36 crore across 136 companies, though still far below the maximum of Rs 2,995.34 crore. For Univest, the sector takeaway is balanced: the company appears stronger than the industry on return ratios, while valuation is richer than the median, especially on P/B. That helps explain why any Price Fall in the stock attracts attention in Market News and BSE News.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,995.34	31.94	0.47	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,836.87	69.35	10.97	18.65	22.17
Hikal Ltd.	HIKAL	2,619.52	0	2.24	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,605.37	45.02	1.73	-0.78	8.31
Panacea Biotec Ltd.	PANACEABIO	2,450.34	0	3.04	0	5.36

Shree Ganesh Remedies Ltd. (SGRL) has a P/E ratio of 44.34x compared with the displayed peer median of 31.94x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 21.18% compares with a peer median of 0% across the companies shown in the table. ROCE stood at 27.51% versus the displayed peer median of 8.31%, providing a capital-efficiency comparison. Shree Ganesh Remedies Ltd. (SGRL) has a market capitalisation of Rs 783.16 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Shree Ganesh Remedies Share Price is easier to interpret when placed against listed pharmaceutical peers in the supplied comparison set. On market capitalisation, the company at Rs 783.16 crore is materially smaller than peers such as Dishman Carbogen Amcis Ltd. at Rs 2,995.34 crore, Beta Drugs Ltd. at Rs 2,836.87 crore, Hikal Ltd. at Rs 2,619.52 crore, Ind-Swift Laboratories Ltd. at Rs 2,605.37 crore and Panacea Biotec Ltd. at Rs 2,450.34 crore. It is also below Sai Parenteral's Ltd. at Rs 2,441.79 crore, Solara Active Pharma Sciences Ltd. at Rs 2,436.78 crore, Fredun Pharmaceuticals Ltd. at Rs 2,304.91 crore, Venus Remedies Ltd. at Rs 2,214.91 crore and NGL Fine-Chem Ltd. at Rs 2,107.85 crore.

Valuation is mixed in relative terms. The company’s P/E of 44.34 is above Dishman Carbogen Amcis at 31.94, above Venus Remedies at 19.99, above NGL Fine-Chem at 37.2, and slightly below Ind-Swift Laboratories at 45.02. It is notably below Beta Drugs at 69.35, Fredun Pharmaceuticals at 56.53 and Sai Parenteral's at 174.73. On P/B, Shree Ganesh Remedies at 4.2 is much higher than Dishman Carbogen Amcis at 0.47, Hikal at 2.24, Ind-Swift at 1.73, Panacea Biotec at 3.04, Sai Parenteral's at 3.19 and Solara at 1.96, but lower than Beta Drugs at 10.97, Fredun at 8.44 and NGL Fine-Chem at 6.46.

Profitability compares more favourably. ROE at 21.18% is above Beta Drugs at 18.65, Hikal at 15.22, Sai Parenteral's at 13.9, Fredun at 11.42 and Venus Remedies at 9.85, while trailing NGL Fine-Chem at 27.9. It is also much higher than Dishman Carbogen Amcis at -2.89, Ind-Swift at -0.78 and Panacea Biotec at 0. ROCE at 27.51% is above Hikal at 16.15, Sai Parenteral's at 12.97, Solara at 15.34, Fredun at 13.15, Venus Remedies at 7.89 and Ind-Swift at 8.31, though below NGL Fine-Chem at 33.91. For Univest, the peer picture suggests that Shree Ganesh Remedies Share Price is not obviously cheap, but profitability metrics are comparatively strong.

Why Investors Are Watching Shree Ganesh Remedies

Shree Ganesh Remedies Share Price is being watched because today’s decline is large enough to move the stock into the top decliner conversation, while the company’s valuation and profitability ratios still present a more nuanced backdrop than the price action alone suggests. In Stocks Falling Today screens, investors often look first at the percentage move. In Shree Ganesh Remedies Share News, however, the bigger question is whether the decline changes the way the stock should be viewed relative to its sector and peer set.

• Price action: The stock fell 9.22% to Rs 484 from Rs 533.15, after opening at Rs 530.55 and falling to Rs 476.75.
• Market cap context: At Rs 783.16 crore, it is a micro-cap stock whose move was large enough to qualify under the event screen.
• Valuation: P/E is 44.34 and P/B is 4.2, both relevant for judging whether the stock still trades at a premium.
• Profitability: ROE of 21.18% and ROCE of 27.51% are stronger than the industry median and average figures supplied.
• Trading activity: BSE volume stood at 36,073 shares with turnover of Rs 1.75 crore, keeping the stock visible in daily Market Movers.

What investors may monitor next is whether Shree Ganesh Remedies Share Price stabilises after today’s weak session or continues to face selling pressure, and whether any fresh company disclosure or broader sector move emerges. For now, the supplied data supports only the fact of the decline, the valuation framework around it, and its standing within the Healthcare and Pharmaceuticals & Drugs universe tracked by Univest.

About Shree Ganesh Remedies

Shree Ganesh Remedies Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry in the supplied dataset. That industry placement matters because it frames how the market evaluates the company’s earnings multiple, book value multiple, return ratios and market capitalisation against other listed drug and pharmaceutical businesses.

From the available verified data, the company is best understood as a smaller listed pharmaceutical player with a market capitalisation of Rs 783.16 crore. Within its industry benchmark of 136 companies, it is larger than the median company by market capitalisation, which is Rs 146.81 crore, and also above the average of Rs 489.36 crore. At the same time, it remains much smaller than the biggest names in the peer set, where market caps extend above Rs 2,000 crore and up to Rs 2,995.34 crore.

Shree Ganesh Remedies Share Price therefore occupies an interesting position in the market: it belongs to a micro-cap category for event screening, yet its valuation and return ratios place it into more serious comparative discussions. Its P/E of 44.34, P/B of 4.2, ROE of 21.18% and ROCE of 27.51% give investors a compact snapshot of how the market currently prices the business and how efficiently the business has been using capital. For readers following Shree Ganesh Remedies Company News and Shree Ganesh Remedies Latest News, that industry positioning is the essential starting point.

Track Shree Ganesh Remedies Share Price on Univest

Use Shree Ganesh Remedies Ltd. (SGRL) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who want to follow Shree Ganesh Remedies Share Price more closely can track it on Univest alongside daily market updates and stock analysis tools. Univest helps users monitor live share price moves, day high and low, previous close comparisons, market capitalisation, valuation ratios such as P/E and P/B, profitability measures including ROE and ROCE, and broader sector context. Users can also follow 52-week levels, shareholding pattern when available, and market insights around BSE-listed stocks. For readers searching for Shree Ganesh Remedies Share Price Live, Shree Ganesh Remedies Share Price Update or Shree Ganesh Remedies Stock Performance, Univest offers a structured way to keep the data in one place without turning the move into a recommendation.

Frequently Asked Questions

What is the latest Shree Ganesh Remedies Share Price Today?

Ans. Shree Ganesh Remedies Share Price Today was Rs 484 at the time captured in the data. The stock was down Rs 49.15, or 9.22%, from its previous close of Rs 533.15 on 14 August 2026.

Why is Shree Ganesh Remedies Stock Falling Today?

Ans. The supplied data confirms that the stock fell 9.22% in a single session, making it a notable top decliner. However, the dataset does not establish a company-specific catalyst, only the verified price fall and trading activity.

What were the day high and day low for Shree Ganesh Remedies shares?

Ans. The stock opened at Rs 530.55, which was also the day’s high, and later touched a low of Rs 476.75. That wide intraday range shows sustained weakness after the opening level rather than an afternoon reversal.

What is the market capitalisation of Shree Ganesh Remedies Ltd.?

Ans. Shree Ganesh Remedies Ltd. had a market capitalisation of Rs 783.16 crore in the supplied data. That places the stock in the Micro Cap category for the event screen used to identify significant same-day price falls.

How much volume was traded in Shree Ganesh Remedies on BSE?

Ans. Trading volume on BSE stood at 36,073 shares, which also matched the current and total volume in the dataset. The corresponding turnover was Rs 1.75 crore, showing visible participation during the decline.

Is Shree Ganesh Remedies expensive based on P/E and P/B?

Ans. The stock’s P/E is 44.34 and P/B is 4.2. Within the same Pharmaceuticals & Drugs benchmark, its P/E is above the median 24.41, while its P/B is above the median 1.75 and average 2.51.

How profitable is Shree Ganesh Remedies compared with its industry?

Ans. Profitability looks relatively strong in the supplied comparison. ROE is 21.18% versus the industry median 10.49%, while ROCE is 27.51% against the median 12.97%, placing the company above central benchmark levels.

What does EPS indicate for Shree Ganesh Remedies?

Ans. Earnings per share is 12.02 in the supplied data. EPS reflects earnings attributable to each share and provides context for the company’s P/E ratio of 44.34, which is the market price relative to earnings.

Does Shree Ganesh Remedies pay a dividend yield?

Ans. The dividend yield in the supplied dataset is 0. That means the current data does not indicate a historical or prevailing payout yield relative to the stock’s market price at the time of the event.

Which sector and industry does Shree Ganesh Remedies belong to?

Ans. Shree Ganesh Remedies belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The sector benchmark used here covers 136 same-industry companies, providing context for valuation, profitability and market-cap comparisons.